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We recently reported that the neuropathic pain medication, gabapentin (GBP; Neurontin),
significantly attenuated both noxious colorectal distension (CRD)-induced autonomic
dysreflexia (AD) and tail pinch-induced spasticity compared to saline-treated cohorts 2–3
weeks after complete high thoracic (T4) spinal cord injury (SCI). Here we employed
long-term blood pressure telemetry to test, firstly, the efficacy of daily versus acute
GBP treatment in modulating AD and tail spasticity in response to noxious stimuli at 2
and 3 weeks post-injury. Secondly, we determined whether daily GBP alters baseline
cardiovascular parameters, as well as spontaneous AD events detected using a novel
algorithm based on blood pressure telemetry data. At both 14 and 21 days after
SCI, irrespective of daily treatment, acute GBP given 1 h prior to stimulus significantly
attenuated CRD-induced AD and pinch-evoked tail spasticity; conversely, acute saline had
no such effects. Moreover, daily GBP did not alter 24 h mean arterial pressure (MAP) or
heart rate (HR) values compared to saline treatment, nor did it reduce the incidence of
spontaneous AD events compared to saline over the three week assessment period.
Power spectral density (PSD) analysis of the MAP signals demonstrated relative power
losses in mid frequency ranges (0.2–0.8Hz) for all injured animals relative to low frequency
MAP power (0.02–0.08 Hz). However, there was no significant difference between groups
over time post-injury; hence, GBP had no effect on the persistent loss of MAP fluctuations
in the mid frequency range after injury. In summary, the mechanism(s) by which acute
GBP treatment mitigate aberrant somatosensory and cardiophysiological responses to
noxious stimuli after SCI remain unclear. Nevertheless, with further refinements in defining
the dynamics associated with AD events, such as eliminating requisite concomitant
bradycardia, the objective repeatability of automatic detection of hypertensive crises
provides a potentially useful tool for assessing autonomic function pre- and post-SCI, in
conjunction with experimental pharmacotherapeutics for neuropathic pain, such as GBP.
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INTRODUCTION
Spinal cord injury (SCI) is a serious health care problem in
the United States striking, on average, 12,000 individuals each
year. Approximately 270,000 Americans are living with the typ-
ically devastating neurological deficits and debilitating somatic
and autonomic reflexes in chronic SCI (see https://www.nscisc.
uab.edu). In particular, complete as well as incomplete SCI above
high-thoracic levels can lead to a potentially life-threatening
hypertensive condition termed autonomic dysreflexia (AD) that
is often triggered by noxious somatic or visceral stimuli below the
injury level (Karlsson, 1999). Due to the disruption of descending
modulating pathways from the brainstem, this syndrome is
characterized by episodic, sympathetically-driven reflexive hyper-
tension which is usually accompanied by intact baroreflex-
mediated bradycardia (Rabchevsky, 2006). Episodes of AD often
cause debilitating symptoms including pounding headache, acute
anxiety, shivering, flushing and sweating (Kewalramani, 1980).
One of the most common triggers of AD is the distension of
pelvic viscera (bladder and bowel) (Snow et al., 1978; Harati,
1997; Krassioukov et al., 2003).
The development of animal models of noxious colorectal
distension (CRD)-induced AD (Krassioukov and Weaver, 1995;
Rivas et al., 1995) to mimic clinical manifestations of fecal
impaction have enabled the detailed analysis of temporal
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dynamics of CRD-induced hypertension (Maiorov et al., 1997b,
1998). Accordingly, the development and severity of AD has
been correlated with extent of aberrant sprouting of nocicep-
tive C-fibers into the spinal cord below the injury (Krenz et al.,
1999; Marsh et al., 2002; Cameron et al., 2006), and glutamater-
gic neurotransmission has been shown to contribute to spinal
viscerosympathetic initiation of episodic hypertension (Maiorov
et al., 1997a).
There is currently no single clinical intervention which effec-
tively attenuates the manifestation of both muscle spasticity
and AD stemming from SCI (Rabchevsky and Kitzman, 2011).
Notably, however, one compound that has been shown to inter-
fere with glutamatergic transmission and is safe for clinical use is
gabapentin (GBP, Neurontin®; Pfizer, New York, NY, USA), which
is approved for the treatment of epilepsy and is widely used off-
label for the treatment of neuropathic pain (Kitzman et al., 2007).
Accordingly, we have been testing the hypothesis that GBP can
alleviate both spasticity and AD by impeding neurotransmission
of noxious stimuli into the spinal cord, thus eliminating a criti-
cal physiological link between these aberrant reflexes. To this end,
we recently reported that acute GBP administration significantly
attenuates both AD and tail spasticity induced by noxious stim-
uli compared to saline-treated cohorts at 2–3 weeks post-injury
(Rabchevsky et al., 2011).
In order to further characterize the effects of GBP and
determine whether it can be administered as a prophylactic,
here we report the results of long-term telemetry experiments
designed to assess (1) whether daily GBP versus saline alters
baseline cardiovascular parameters, (2) the efficacy of chronic,
daily GBP treatment versus acute administration in modulating
experimentally-induced AD and tail spasticity over 3 weeks post-
injury, and (3) whether daily GBP modulates spontaneous AD
events detected using a novel algorithm we have developed based
on blood pressure telemetry data.
MATERIALS AND METHODS
SURGICAL METHODS; IMPLANTATION OF BLOOD PRESSURE
TELEMETRY DEVICES IN DESCENDING AORTA
As described in detail (Rabchevsky et al., 2011), seven days prior
to T4 transection SCI, naïve anesthetized (ketamine, 80mg/kg,
i.p.; xylazine 7mg/kg, i.p.) rats (n = 12) were implanted with tele-
metric pressure transmitters (model TA11PA-C40, Data Sciences
International, Inc., St. Paul, MN) into the descending aorta after
its brief occlusion and securing the probe to the abdominal wall
with silk sutures. The skin was closed with surgical staples after
rinsing abdominal cavity with saline. The animals were then
treated post-operatively, as described below, and blood pressure
was monitored 24/7 to ensure patency of the probes and to obtain
pre-injury baseline data.
SURGICAL METHODS; SPINAL CORD INJURY
All surgical procedures were performed under aseptic condi-
tions using sterilized instruments, following the University of
Kentucky IACUC and the NIH guidelines. One week following
telemetry implantation, the T4 spinal segment of anesthetized
(ketamine, 80mg/kg, i.p.; xylazine 7mg/kg, i.p.) female Wistar
rats (∼225 g) was exposed by T3 laminectomy (n = 12) and the
spinal cord was completely transected with a scalpel blade before
hemostasis was achieved with gelfoam placed into the resection
site, as previously detailed (Cameron et al., 2006; Rabchevsky
et al., 2011). Wounds were then irrigated with sterile saline, the
muscles sutured using 3-0 vicryl and skin openings stapled with
wound clips. Injured rats were housed one per cage with food
and water ad libitum, placed on a heating pad during recovery,
and injected with 10ml Lactated Ringer’s solution s.c. for fluid
replacement. Upon regaining consciousness, post-surgery pain
was alleviated by administering buprenorphine (0.02–0.05mg/kg,
s.c., Reckitt Benckiser, Hull, UK) twice a day for three days.
The injured animals required manual bladder evacuation twice
a day for 2–3 weeks post-injury until spontaneous bladder void-
ing returned with no signs of urinary tract infection. They also
received twice daily injections (s.c.) of antibiotics (33.3mg/kg
Cefazolin, s.c., SoloPak Laboratories, New Gove, IL) and Ringer’s
for 5 days.
TELEMETRICMONITORING OF BLOOD PRESSURE BEFORE AND
AFTER SCI
Following transection SCI, the Dataquest A.R.T. system (Data
Sciences International, Inc., St. Paul, MN) was used for 24/7
telemetric monitoring of pulsatile arterial blood pressure (PAP),
as well as on-demand monitoring of blood pressure prior to,
during, and after noxious CRD. CRD was performed on four
separate days following SCI. Specifically, on days 14, 15, 21,
and 22, injured animals in both chronic treatment groups were
injected with either acute GBP or saline 1 h prior to cardio-
physiology in response to CRD (see Table 1). For each gently
restrained conscious rat, a period of 15min was allowed to pass
to allow them to become quiet after carefully inserting a latex
balloon-tipped catheter (Swan-Ganz Paceport catheter; Baxter
Healthcare Corporation, CA) 2 cm inside the rectum and secur-
ing it to the tail with tape. Prior to each initiation of spinal
viscero-sympathetic reflexes, 30 s of baseline arterial pressure
was recorded. Measurements continued during the gradual (15 s)
inflation of the 10mm long balloon inflation (CRD) with 2ml of
air for a period of 60 s, followed by another 30 s following balloon
deflation. Such CRD expands the colon as would several large
fecal boluses. During a recording period, animals within indi-
vidual cages were placed upon receiver plates and PAP readings
were transmitted to a receiver (PhysioTel Receiver, RPC-1 from
Data Sciences International) as a radio frequency signal integrated
by a data exchange matrix. The two traces for each animal trial
were saved and stored in a selected file for subsequent analyses.
Thus, two separate trials were conducted for each animal sepa-
rated by ∼30min on each of the four testing days. The average
MAP and HR values over the entire dynamic 60 s CRD period
were calculated prior to averaging the values over the two trials
for each animal; the mean MAP and HR values across each treat-
ment group were then derived from summing individual animal
averages.
BEHAVIORAL ASSESSMENT FOR SPASTICITY IN THE TAIL MUSCLES
Between the two trials for each of the four separate days that
CRD was performed (∼30min), spasticity in the tail was assessed
behaviorally using an established scale (Kitzman, 2006; Kitzman
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et al., 2007). Specifically, the response of the tail muscles to a
quick stretch, light stroking (non-noxious stimulus) and a light
pinch (noxious stimulus) applied approximately 10 cm from the
tip of the tail were assessed. Tail manipulations were performed
with the animals lightly restrained and the tail was free to move
over its full length. In this study, the animals displayed either a
stage-2, stage-3, or stage-4 spasticity prior to initiating pharma-
cological intervention (see Table 2). For the purpose of statistical
analysis, responses to quick stretch and pinch were graded using a
five point scale in which 0 = minimal (≤45◦ flexion) response
to the stimulus, 1 = 45–90◦ flexion, 2 = >90–180◦ flexion,
3 = >180–225◦ flexion, 4 = >225–360◦ flexion, and 5 = signifi-
cant coiling of the tail and/or activation of flexors, extensors, and
abductors (writhing) lasting>2 s and the presence of clonus. The
response to light touch was scored using a three point grading
scale in which 0 = no response, 1 = minimal flexion of the tail
away from the stimulus, and 2 = pronounced flexing of the tail
away from the stimulus.
DRUG ADMINISTRATION
Every morning at 9:00 am, beginning the day after SCI, animals
received a daily i.p. injection of either GBP (50mg/kg; Neurontin)
or saline vehicle. Notably, however, on days 15 and 22 the treat-
ment groups were reversed to assess the effects of acute versus
chronic GBP administration on the cardiophysiological responses
to CRD and tail manipulations (see Tables 1 and 2). Importantly,
the half-life of GBP is 5–9 h in humans, which is unaltered fol-
lowing multiple dosing (Goa and Sorkin, 1993; McLean, 1995).
Accordingly, when a person receives GBP 3–4 times per day, the
half-life is still reported as being 5–9 h; thus the required multi-
ple dosages each day. If the half-life altered with multiple dosages,
then once a patient reached the therapeutic dosage (typically
3–4 dosages per day), over time one might expect to be able to
decrease the number of dosages per day since the therapeutic half-
life would increase. However, this does not appear to be the case
with GBP.
DETECTING SPONTANEOUS INCIDENCES OF AUTONOMIC
DYSREFLEXIA
An algorithm was developed to automatically detect spon-
taneous AD events based on the 24 h blood pressure and
heart rate (HR) telemetry data. Concurrent values for mean
arterial blood pressure (MAP) and HR were recorded using
DataQuest (Data Sciences International, Inc., St. Paul, MN)
at 2 s intervals for 4 days pre-injury and 22 days following
T4 spinal cord transection. Example waveforms of MAP and
HR are shown in Figures 1 and 4. The algorithm processed
these waveforms to effectively estimate the number of instances
where an abnormally sharp MAP increase was accompanied
by HR decrease, as illustrated in Figure 3. This was imple-
mented with a program written in Matlab (TheMathWorks, Inc.,
Natick, MA).
The MAP and HR signals were initially low-pass filtered at a
0.04Hz cut-off frequency with a 6th order Butterworth filter to
smooth out transient spikes (less that 12.5 s duration) and limit
their impact on threshold crossings. A baseline comparison for
MAP was created by a moving average window of 240 s. This was
used for comparing the MAP values at 25 s after the end of the
averaging window. Note that in Figure 3, the MAP values were
delayed by 25 s relative to the baseline average so comparisons
could be more easily visualized. A MAP peak was associated with
a detected AD event when simultaneous numerical conditions
were met, as illustrated in Figure 3. The following are the con-
ditions with values used in the algorithm for results presented in
this report:
(1) MAP peak exceeds the baseline by Tp = 10mmHg or greater.
(2) The difference between the MAP peak value and the MAP
minimum value within the previous Tr = 35 seconds must
be Ts = 20mmHg or greater than this peak (i.e., MAP swing
must be sufficiently large and fast).
(3) The HR must drop by Th = 10 bpm or greater within the
MAP event interval, defined as staring with the MAP exceed-
ing Tp and ending when it drops below this same value (see
example in Figure 3A). The maximum HR associated with
the drop must occur within the first 75% of this interval
and the minimum HR value must occur after this maximum
value and within 5 s beyond the end of the MAP interval (i.e.,
the HR drop must be sufficiently close to the elevated MAP
event).
SPECTRAL ANALYSIS
To examine persistent MAP dynamics between groups, a power
spectral density (PSD) analysis was performed. This analysis
complements the result for the spontaneous AD events in that
it detects differences in persistent dynamics, since it averages
over the observation interval. Sparse transient events are aver-
aged out in this case. The PSDs were computed using Welch’s
method (Proakis and Manolakis, 1996) from data recorded for
4 h following the daily injections. The raw pulsatile blood pres-
sure signal was originally sampled at 512Hz, and re-sampled to
50Hz after an anti-aliasing filter was applied. Spectral magni-
tudes were computed from 128 s segments with linear trends
removed, and a 50% overlap was used between consecutive
segments.
SPINAL CORD TISSUE PROCESSING AND HISTOLOGY
After final analyses, all injured rats were overdosed with sodium
pentobarbital and transcardially perfused with 4% paraformalde-
hyde in PBS. Dissected spinal cords from T4-transected rats
were stored for long term storage at 4◦C in 20% sucrose/PBS
containing 0.02% sodium azide.
STATISTICS
All data were both collected and analyzed in a blinded manner, as
routinely performed in our published pharmacological studies.
Notably, all analyses were performed by individuals blinded with
respect to treatment. For comparisons of CRD-induced MAP
and HR changes, unpaired Student’s t-tests, with bonferroni cor-
rection factor when appropriate, were used between saline- and
GBP-treated groups. Specifically, we compared the average MAP
and HR values over the entire 60 s CRD period, and averaged
the values over the two trials for each animal. To compare AD
events over time between groups, a repeated measures analysis of
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variance (ANOVA) was performed, followed by Fischer’s PLSD
when appropriate. Each behavioral test (tail responses to stretch,
noxious pinch, and non-noxious light touch, as well as presence of
clonus) was compared using theMann-WhitneyU test for ordinal
data. PSD data were analyzed via power ratios between low and
mid frequencies ranges and 95% confidence limits for each group
were computed. Statistical significance was set a priori at p < 0.05
for all analyses.
VALIDATION OF ALGORITHM
The parameters of the AD algorithm were optimized using a data
set consisting of 156 h of data labeled by an observer. The level of
agreement between human observation and the automatic algo-
rithm was assessed by estimating the probability of agreement on
humanly detected AD events (47) from 169 h of telemetry data
from 3 SCI rats. The results are described by two metrics, a prob-
ability of positive agreement (when the algorithm and observer
identified the same time segment as containing an AD event), as
well as a negative agreement rate (how often per second the algo-
rithm identifies an AD event when the human observer did not).
The test resulted in a positive agreement probability of 0.87 and a
negative agreement rate of 6.0 × 10−5 per second (approximately
five detections per day). In addition, the algorithm was applied
to 72 h of pre-injury data (where no AD events are expected) and
resulted in two detections per day, which is considered a false-
detection rate of 2.3 × 10−5 per second. Given the expected level
of human error, especially for large data sets, this is considered a
good agreement.
RESULTS
EFFECTS OF DAILY GBP TREATMENT ON RESTING BLOOD
PRESSURE AND HEART RATE
During the experiment, one GBP-treated animal died shortly
after surgery for uncertain reasons. All animals were housed one
per cage and Figure 1 demonstrates blood pressure recordings
gathered telemetrically from a rat prior to SCI over a 24 h period.
Every morning, beginning the day after SCI, the injured ani-
mals received an injection (i.p.) of either GBP or saline vehicle.
As depicted in Figure 2, assessments over 24 h periods across
days post-injury revealed no significant treatment effect (p > 0.1)
on average daily MAP and HR values, but there was a signifi-
cant effect of days post-injury on both MAP [F(1, 21) = 7.282,
p < 0.0001] and HR [F(1, 21) = 13.23, p < 0.0001] values. Post-
hoc analyses revealed a significant (p < 0.05) decrease in MAP
values at 1 day post-injury (DPI) compared to pre-injury val-
ues, as well as compared to 3 and 4 DPI. The ensuing MAP
values between 5 and 13 DPI were again significantly (p < 0.05)
lower compared to pre-injury. Notably, however, from 14 to
22 DPI there were significant (p < 0.05) elevations of daily
MAP compared to 5–13 DPI that approximated pre-injury val-
ues. For accompanying HR values, there were significant (p <
0.05) decreases from 8 to 13 DPI compared to 1 DPI which
was followed by significant (p < 0.05), diametrically oppo-
site increases in HR values from 14 to 22 DPI compared to
1 DPI. However, there was no significant treatment by days
effect on either daily MAP [F(1, 21) = 0.865; p = 0.636] or HR
[F(1, 21) = 0.383; p = 0.994]. Overall, there appeared to be a
FIGURE 1 | Representative tracesofmeanarterial pressure (A;mmHg) and
heart rate (B; BPM) recorded from a naïve animal 1 day prior to T4 spinal
cord transection.Datawas gathered telemetrically over a 24-h period using an
implantable probe that was inserted into the descending aorta. Animals were
housed one per cage to allow for individual telemetric monitoring. Receivers
placed beneath each animal’s cage telemetrically relayed signals into a data
exchange matrix, where the signal was integrated into files to be opened with
the Dataquest A.R.T. software package for subsequent analyses.
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FIGURE 2 | Graphs representing both mean arterial pressure (A, MAP)
and heart rate (B, HR in beats per minute) across days post-injury
(DPI) gathered telemetrically over 24h periods, beginning at
9:00am following injections of either Saline or gabapentin (GBP).
Due to the overall variability in both outcome measures, there were no
significant differences between treatment groups for daily MAP and HR
values. The conspicuous sustained elevation in both daily MAP and HR
values beginning on days 14–15 post-injury that approached pre-injury values
are interesting. n = 6 Saline; n = 5 GBP (50mg/kg). Symbols represent group
means ± SEM error bars.
conspicuous elevation in both MAP and HR values beginning
two weeks post-injury that remained elevated, approaching pre-
injury values; the significance of this alteration is uncertain,
although it does correspond to the development of AD in this
model.
ACUTE, NOT CHRONIC GBP TREATMENT REDUCES INDUCED
AUTONOMIC DYSREFLEXIA AND TAIL MUSCLE SPASTICITY
As detailed in “Materials and Methods” and depicted in Table 1,
on days 15 and 22, the animals receiving GBP every morning were
injected with a single dose of saline (acute saline) 1 h prior to
assessments, whereas the animals receiving saline every morn-
ing were given a single dose of GBP (acute GBP) 1 h prior to
assessments. It was found that only acute GBP treatment signif-
icantly reduced CRD-induced MAP increases by approximately
two-fold compared to acute saline treatment, irrespective of
chronic morning treatments. Bradycardia also appeared reduced
with GBP at all time points examined, but variability precluded
significant differences. As detailed in “Materials and Methods”
and depicted in Table 2, when tail spasticity was assessed in the
same injured animals in response to light touch, stretch and
noxious pinch, only acute GBP treatment had a significant and
striking effect in virtually abolishing all three measures of tail
spasticity.
EFFECT OF DAILY GBP TREATMENT ON THE INCIDENCE OF
SPONTANEOUS AUTONOMIC DYSREFLEXIA
We developed a novel algorithm to detect spontaneous events of
AD based on the 24 hMAP andHR telemetry data. The algorithm
was developed and thresholds determined from a sample data set
www.frontiersin.org August 2012 | Volume 3 | Article 329 | 5
Rabchevsky et al. Gabapentin alleviates autonomic dysreflexia
Table 1 | Quantified changes in mean arterial pressure (MAP) and heart rate (HR) measurements from baseline during one minute of noxious
colorectal distension (CRD) in injured rats treated chronically (daily morning) with either Saline or GBP.
Acute administration (Time points) Chronic treatment groups
MAP (mmHg) HR (beats per min)
Saline GBP Saline GBP
Saline
14 DPI
19.7± 2.5 – −43.8 ± 12.2 –
GBP – 9.0 ± 3.6∗ – 4.1 ± 10.9∗
Saline
15 DPI
– 26.3 ± 3.8 – −13.7 ± 10.1
GBP 5.9± 1.1∗∗∗ – −16.0 ± 4.6 –
Saline
21 DPI
38.0± 3.4 – −36.1 ± 19.5 –
GBP – 14.7 ± 4.7∗∗ – −16.3 ± 15.5
Saline
22 DPI
– 34.3 ± 3.5 – −50.9 ± 22.0
GBP 19.4± 3.1∗ – −6.8 ± 7.2 –
Both chronic treatment groups were subjected to CRD after either Acute GBP or Acute Saline injections prior to assessments on alternating days (days 14–15 and
21–22). Acute GBP treatment significantly reduced CRD-induced MAP increases by approximately two-fold compared to Acute Saline treatment, irrespective of
Chronic (daily morning) Treatment Groups. While bradycardia appeared to be reduced at all time points examined, the variability precluded significant differences.
Values represent group means ± SEM. ∗p ≤ 0.05, ∗∗p ≤ 0.005 and ∗∗∗p ≤ 0.001 between Acute GBP versus Acute Saline groups at all Administration Time Points.
Table 2 | Behavioral responses of the tail musculature 2–3 weeks following T4 spinal cord transection (same rats as in Table 1) in response to
Touch (Left), Stretch (Middle) and Pinch (Right) 1 h following the administration of Saline or GBP.
Acute administration (Time points) Chronic treatment groups
Saline GBP Saline GBP Saline GBP
Tail touch Tail stretch Tail pinch
Saline
14 DPI
2.0 ± 0.2 – 5.0 ± 0.2 – 5.0 ± 0.0 –
GBP – 0.0 ± 0.2∗ – 0.0± 0.4∗ – 1.0 ± 0.4∗
Saline
15 DPI
– 2.0 ± 0.0 – 5.0± 0.4 – 5.0 ± 0.6
GBP 0.0 ± 0.2∗ – 0.0 ± 0.3∗ – 0.0 ± 0.2∗ –
Saline
21 DPI
2.0 ± 0.2 – 5.0 ± 0.0 – 5.0 ± 0.0 –
GBP – 0.0 ± 0.2∗ – 0.0± 0.4∗ – 0.0 ± 0.4∗
Saline
22 DPI
– 2.0 ± 0.0 – 5.0± 0.0 – 5.0 ± 0.0
GBP 0.5 ± 0.3∗∗ – 0.0 ± 0.8∗∗ – 0.0 ± 0.8∗∗ –
Response to Tail Touch was scored on a 2 point scale in which 0 = no spasticity and 2 = severe spasticity. Responses to Tail Stretch and Tail Pinch were scored on a
5 point scale in which 0 = no spasticity and 5 = severe spasticity. Quantitative analyses confirmed the striking effect of Acute GBP treatment in virtually abolishing
all three measures of tail spasticity, irrespective of the Chronic (daily) treatment over days post-injury (DPI). ∗p < 0.05 Values represent group medians ± SEM for
visualization purposes only.
with AD events labeled by human observers of the MAP, baseline
MAP, and HR from several animals (about 60 h of data). An illus-
tration of a detected AD event is shown in Figure 3. To establish
the algorithm relative to human identified events, the algorithm
was run on an independent set of test data where AD events were
identified by human observers (see “Materials and Methods,”
Statistical analyses). Results showed an agreement of greater than
80% with humanly detected events. For the times corresponding
to no humanly detected AD events, the algorithm detected events
at a rate of 0.0004 events per second, which corresponds to about
1 event every 42min.
Through validation of humanly observed events that the pro-
gram detected (indicated by green and red lines in Figure 4),
the optimal parameters which corroborated humanly observed
events were subsequently used to calculate spontaneous events
of AD in both treatment groups over days post-injury. Notably,
when the pre-injury data was analyzed with these algorithm
parameters, event detections were infrequent (1–3 events/day
in the 4 days prior to injury) relative to post-injury detections
(5–30/day). This infers that the algorithm detects aberrant physi-
ology rather than typical MAP and HR dynamics.
When the algorithm was applied to the data sets from both
treatment groups, it calculated the number of detected sponta-
neous AD events over days post-injury (Figure 5). In particular,
it was used to generate both the number of detected AD events
over 24 h periods between the chronic saline and GBP treat-
ment groups (Figure 5A), as well as the number of detected
AD events in the first 4 h following daily saline and GBP injec-
tions (Figure 5B). In both cases, negligible events were detected
prior to injury, as expected based on the algorithm parameters.
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FIGURE 3 | Graphic examples of conditions used to detect an autonomic
dysreflexia (AD) event. (A) Filtered mean arterial pressure (MAP) signal
with baseline (gray line) and three thresholds used in conditions for event.
(B) Corresponding filtered heart rate (HR) signal within MAP event interval
shows threshold for HR drop condition. Heart rate signal does not have a
baseline.
In the first several days following SCI, there appeared to be inex-
plicable detected AD events only in the GBP treatment group.
Subsequently, however, until two weeks post-injury, the detected
AD events remained only marginally elevated from pre-injury
values for both groups. After 14 days post-injury, there appeared
to be increases in the number of AD events detected in both
treatment groups compared to pre-injury values; over 24 h or
4 h after daily injections. When a repeated measures ANOVA was
run between treatment groups and the numbers of detected AD
events across 22 days post-injury, there was no significant treat-
ment effect (p > 0.1). When the data between treatment groups
was collapsed and assessed similarly from 14 days post-injury
onwards, a time when severe AD is known to be present, there
was still no significant treatment effect (p > 0.1) over the 24 h
or first 4 h periods (Figures 5A,B). While there was a signifi-
cant effect of days post-injury for 24 h period values [F(1, 8) =
2.921; p < 0.01], this was not the case for the first 4 h post
daily injection [F(1, 8) = 1.170; p = 0.329]. Accordingly, there
was no significant treatment by days interaction for AD events
over 24 h periods [F(1, 8) = 0.974; p = 0.463] (Figure 5A) or dur-
ing the first 4 h after daily injection [F(1, 8) = 1.67; p = 0.121]
(Figure 5B).
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FIGURE 4 | Graphic examples of autonomic dysreflexia (AD) events
detected over a 24-h period in an injured animal, employing the
algorithm. Signals for mean arterial pressure (MAP) (A,B) and heart rate
(HR) in beats per minute (C,D) from a saline-treated, injured rat 15 days
following T4 spinal cord transection. In the MAP and HR traces, the horizontal
red lines represent the baseline trace, while the blue lines correspond to the
raw signals. The HR signal does not include a baseline, only the raw blue
traces. In (B) and (D), shown at higher magnification, the green lines indicate
the beginning of an AD event, while red lines coincide with the end of the
event.
SPECTRAL ANALYSIS OF BLOOD PRESSURE
We then sought correlations between the visible reductions of
AD events in GBP-treated animals and trends in the spectral
analysis of blood pressure. Critically, traditional spectral analy-
ses do not pick up this clinically relevant event, highlighting the
importance of the parameters we used to define an AD event
in the algorithm. As depicted in Figure 6, spectral analysis of
blood pressure only demonstrated the significant loss of a reg-
ulatory mechanism after SCI with dynamics in the 0.2–0.8Hz
(Mid) range (Figure 6A), with no consistent differences between
treatment groups. Importantly, this does not negate the AD detec-
tions found using the algorithm and suggests that GBP did not
impact the persistent changes resulting from the injury. The error
bars in Figure 6B represent the 95% confidence limits of the
mean power (PSD) ratio estimates from each group on each day.
Note that for each day post-injury, the 95% confidence limits
overlap; however for the pre- and post-injury days their 95% con-
fidence limits do not overlap, indicating a significance difference
(p < 0.05).
DISCUSSION
Here we report the results of long-term radio-telemetry experi-
ments designed to determine, firstly, whether daily GBP admin-
istration for 3 weeks post-SCI versus saline altered baseline
cardiovascular parameters, as well as AD elicited by noxious
CRD. Notably, the same injured animals were also assessed for
induced tail muscle spasticity, both distinct debilitating secondary
reflexes following SCI that are often triggered by noxious stimuli
below the SCI level (Rabchevsky and Kitzman, 2011). Daily GBP
administration did not have significant effects on cardiovascular
parameters, but there were trends for elevated MAP andHR com-
pared to saline, notably in the first two weeks post-injury. On the
contrary, and in support of our recent findings (Rabchevsky et al.,
2011), acute GBP treatment significantly attenuated experimen-
tally induced AD and tail spasticity, irrespective of chronic daily
morning treatments.
GBP is currently provided as a prophylactic for neuropathic
pain, indicating chronic administration. Therefore, we sought
to determine whether GBP can be effectively taken orally near
the onset of AD (acutely) to alleviate the debilitating reflexes.
GBP possesses multiple cellular mechanisms and demonstrates
the potential to help decrease the manifestation of spasticity
in the chronic SCI population (Gruenthal et al., 1997; Priebe
et al., 1997). Inhibition of glutamatergic transmission may be
pre-eminent in mediating its therapeutic effects in epilepsy,
neuropathic pain, and spasticity (Wheeler, 2002). Specifically,
gabapentin has been shown to inhibit presynaptic glutamate
release (Shimoyama et al., 2000; Maneuf and McKnight, 2001;
Maneuf et al., 2004; Coderre et al., 2005, 2007). Moreover, glu-
tamatergic neurotransmission has been shown to contribute to
spinal viscerosympathetic initiation of episodic hypertension dur-
ing experimental AD (Maiorov et al., 1997a) as well as induced
tail muscle spasticity (Kitzman et al., 2007). Alternatively, GBP
has been reported not to work by modulating presynaptic Ca2+
channel release; instead, it serves as a thrombospondin recep-
tor which, when bound, inhibits new synapse formation in a
murine model of whisker barrel de-afferentation (Eroglu et al.,
2009). However, the latter study reported that GBP did not elim-
inate established synapses, inferring that inhibition of synapse
formation with chronic daily GBP treatment cannot explain the
mechanisms by which acute GBP treatments were effective in
ameliorating nociceptive spinal reflexes after SCI.
Based on this and our previous findings (Rabchevsky et al.,
2011), our initial expectation was that daily GBP may lower basal
MAP, in part, by reducing the incidence of spontaneous AD.
In order to address this intriguing possibility, we developed an
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FIGURE 5 | Using the algorithm described in “Materials and Methods,”
these graphs illustrate detected autonomic dysreflexia (AD) events
for each chronic (daily) treatment group over 24h (A) versus the
first 4 h (B) following daily injections of gabapentin (GBP) or Saline.
Although there appeared to be fewer overall spontaneous AD events
following GBP treatment at later days post-injury (DPI), variability
precluded significant differences. Symbols represent group means ± SEM
error bars.
algorithm to detect spontaneous events of AD based on 24 hMAP
and HR data gathered over 3 weeks. Once validated, we found
that chronic GBP treatment reduced daily spontaneous AD events
and, more prominently, within the first 4 h after administration.
The appearance of AD events and, accordingly, the suppressive
effects of GBP became apparent two weeks after SCI, which cor-
responds to the time course of AD development (Krassioukov
and Weaver, 1995; Mayorov et al., 2001; Rabchevsky, 2006).
Interestingly, we observed remarkable cardiophysiological alter-
ations in mean daily MAP and HR values in both treatment
groups that began to appear following initial CRD trials on days
14–15. While, we do not have data for control injured rats, this
suggests that noxious CRD may lead to profound adaptations
in the spinal cord of animals with complete SCI, irrespective of
treatment.
Several weeks following experimental SCI, CRD induces a
rapid increase in MAP that are usually accompanied by varying
degrees of bradycardia; the clinical definition of AD (Karlsson,
1999). Critically, such AD episodes can last as long as the noxious
CRD is applied and the magnitude of MAP increases is typically
in the range of 20–50mmHg above baseline, as shown in this and
previous studies (Krassioukov and Weaver, 1995; Cameron et al.,
2006; Hou et al., 2008). This is a key distinction between detect-
ing spontaneous AD events versus those elicited by experimental
CRD, the latter of which establishes a stable baseline MAP prior
to assessments. Indeed, in developing the AD algorithm we could
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FIGURE 6 | (A) Power spectral density (PSD) analysis averaged over all animals
for one day pre- and 18 days post-injury (DPI). The key difference resulting
from the injury is the loss of mid frequency (Hz) dynamics. These differences
were typical of the others days as well. (B) For day-by-day comparisons, an
average ratio between the power in low frequency range (0.02–0.08) and mid
frequency range (0.2–0.8) was computed for each group. A decrease in this
ratio represents a shifting of power to the lower frequencies. The results are
presentedwith 95%confidence limits for theerror bars. Note that the horizontal
dashed line indicates that the 95% intervals between pre-and post-injury are
non-overlapping.The relative loss inmid frequencydynamics overDPI is clearly
seen by the distance betweenmeans from the pre-injury cases. However,
there is no consistent difference between treatment groups over DPI.
not find persistent prolonged MAP increases accompanied by
bradycardia, most notably ≥15mm Hg above baseline estab-
lished by extended averaging windows and low-pass filtered MAP
signals. It is uncertain whether the sparse transient AD events
detected are a reflection of either fecal impaction or distended
bladder, but the same injured rats responded to noxious CRD
with significant AD, except for those receiving GBP acutely before
assessments. Importantly, however, the spontaneous AD events
detected over days post-injury were not significantly altered by
daily, chronic GBP treatment.
Based on seminal rodent AD modeling studies (Krassioukov
and Weaver, 1995; Rivas et al., 1995; Maiorov et al., 1997b;
Krenz et al., 1999; Mayorov et al., 2001; Marsh et al., 2002), our
own published reports have consistently reported CRD-induced
changes in MAP versus changes in systolic arterial blood pressure
(SAP). To our knowledge, only recently have SAP changes been
reported as a primary indicator of experimentally-evoked AD
(Inskip et al., 2012). Nevertheless, we reanalyzed our data sets
for the current and other ongoing studies to establish the
applicability of reporting changes in SAP values instead of MAP.
While the magnitudes of CRD-induced SAP increases were found
to be greater than MAP changes, the patterns and statistical
differences were unaltered. Accordingly, we have reported the
MAP changes evoked by CRD as well as spontaneous AD events
detected with the algorithm.
Alternatively, it is documented in other reports, experimen-
tal and clinical, that AD episodes can also be accompanied
by tachycardia, and we have observed many instances of such
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occurrences in this and previous studies. However, regarding
the algorithm, and in line with all our previous reports, we
have operationally defined AD as a MAP increase concomitant
with bradycardia (Krassioukov and Weaver, 1995; Rivas et al.,
1995; Karlsson, 1999). It is also appreciated that based upon our
required bradycardia inclusion, we may have missed otherwise
detected AD episodes. While we did observe instances of tachycar-
dia during CRD-induced MAP increases (see Table 1), the overall
HR changes ranged from −60 to +4 bpm. Accordingly, we can-
not predict how many spontaneous ≥10mm Hg increases were
accompanied by tachycardia since the algorithm parameters were
not set to capture such events. Despite this caveat, such a lim-
itation is based on the user-defined parameters applied to the
algorithm and, therefore, speaks to its broad applicability. For
example, to re-define an AD event the algorithm can be modi-
fied to detect any chosen supra-threshold MAP increase for any
given duration, but when accompanied by either tachycardia,
bradycardia or both.
We chose 50mg/kg dosage (i.p.) for this study since we already
documented that this dosage and route given acutely completely
eliminated spasticity and significantly abrogated CRD-induced
AD in spinal rat models (Kitzman et al., 2007; Rabchevsky et al.,
2011). This dosage is on the low side of what has been employed
in rat models of neuropathic pain, some up to 300mg/kg (Yoon
and Yaksh, 1999; Coderre et al., 2007), and in mice it has been
shown that up to 1000mg/kg does not affect motor performance
(Czuczwar et al., 2003). Also, there is no reported change in Roto-
rod performance one hour after each of four consecutive daily
injections of 100mg/kg GBP (i.p.), and there are no reported
differences in the half-life between GBP administered i.v. or i.p.
(Xiao et al., 2007). The issue that remains unresolved, therefore,
is whether a once daily injection of GBP is sufficient to have
potential effects on spontaneous daily AD events detected by the
algorithm.
The AD event detection algorithm has the advantage of con-
sistently applying the same rules for every case, and while the
human observers are aware of these rules, their ability to recog-
nize the signal dynamics is limited by the need for sufficiently
large swings in HR and MAP (relative to surrounding signals)
to catch their attention. Therefore, the additional AD events cap-
tured by the algorithmwere events that fit the definition, but were
missed by the human observers either due to fatigue or the signal
changes too close to the thresholds. Notably, there were insignif-
icant detections in pre-injury data, validating injury-induced
cardiovascular alterations. The missed AD events by the algo-
rithm on humanly detected events were due, in part, to human
error where a large jump in HR or MAP may have swayed a deci-
sion when both signals did not meet the criteria. On the other
hand, there were cases where some transients were not entirely
filtered out causing spurious threshold crossing and shortening
event intervals. Humans would typically overlook these crossings,
especially if other signal cues suggested the AD event was occur-
ring. In summary, the algorithm showed good agreement with
humanly identified events and provided a repeatable method for
determining number of AD events, not dependent on human sub-
jectivity or variability, and thus a useful tool when large amounts
of data are available.
Although we found that daily GBP after SCI insignificantly
elevated both MAP and HR values compared to daily saline treat-
ment, notably between 1 and 2 weeks post-injury, in the current
study design we did not include a sham injured GBP-treated
group to determine its influences on MAP and HR compared
to sham injured vehicle-treated rats. Importantly, however, we
did analyze pre-injury data for each animal, which served as
internal baseline controls for all cardiophysiological outcome
measures in both injured treatment groups. Accordingly, such
controls ensured reliability and validity of spectral analyses. The
loss in the MAP fluctuations in the mid frequency range after
SCI were shown to be significant, as demonstrated by the PSD
comparisons of Figure 6. This strongly suggests that the regula-
tory mechanisms lost after SCI generate MAP fluctuations with
periods on the order of 1.25–5 s (0.2–0.8Hz). It is worth not-
ing that comparison of spectra before and 18 days post-injury
(Figure 6A) showed differences in the Mid frequency range, a
region that has been associated in rat with sympathetically medi-
ated effects upon blood pressure variability (Brown et al., 1994;
Julien et al., 2003). Importantly, similar blood pressure fluctua-
tions must occur within many intervals used in PSD estimation
to detect such events. In other words, the blood pressure signals
from the AD events were not sufficiently stationary to emerge in
the spectral analysis and, accordingly, such analyses were blind to
sparse transient events that we defined as AD. This stresses the
importance and significance of detecting transient irregular AD
events independently of spectral analysis, since frequency domain
analyses are restricted to identify activity that is persistent over the
observation epoch. Such analyses do indicate, therefore, that GBP
does not affect the persistent dynamics of MAP related to SCI.
In summary, we designed a preclinical study to develop a treat-
ment for chronic SCI individuals who continually suffer from
secondary complications, notably abnormal muscle spasms and
autonomic spinal reflexes. There is currently no pharmaceutical
intervention which is known to effectively attenuate neuropathic
pain as well as the manifestation of both muscular spasticity and
AD after chronic SCI. While the clinical significance of the per-
sistent MAP fluctuations associated with SCI is unclear, transient
AD events directly impact the individual with SCI and, therefore,
analyses directed at detecting and characterizing these event are
critical for assessing treatments for SCI patients. Consequently,
this quantitative experimental study was requisite to establish
proof-of-principle prior to direct clinical application employing
a two-pronged approach designed to alleviate dissimilar aberrant
neurologic reflexes with a single drug, GBP. Such preclinical data
appears to support the novel indication of GBP for the treatment
and maintenance of both spasticity and AD following SCI.
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